Clinical trialUNITERAREApr 15
Researchers are looking for patients with a specific type of blood cancer called Philadelphia chromosome positive acute lymphoblastic leukemia to test a new treatment combination. The treatment uses chemotherapy drugs (EPOCH), sometimes combined with rituximab (a protein therapy), plus a targeted drug called ponatinib. This is a Phase 2 trial, meaning it's testing whether the treatment works and is safe in a larger group of patients.
WHY IT MATTERSThis trial is now actively recruiting patients with newly-diagnosed Ph+ ALL/lymphoma and offers access to ponatinib, a third-generation tyrosine kinase inhibitor that may improve outcomes for this aggressive blood cancer.
Clinical trialUNITERAREApr 5
Researchers are testing a new cancer treatment that takes a patient's own immune cells, modifies them in a lab to recognize and attack their specific cancer, and then puts them back into the body. This Phase 1 trial is for people with blood cancers like leukemia and lymphoma. The treatment is personalized—each patient's cells are customized based on their individual cancer's unique mutations.
WHY IT MATTERSThis trial offers patients with hematologic malignancies access to a cutting-edge personalized immunotherapy that targets their cancer's unique mutations, potentially offering a new treatment option for those who may have limited alternatives.
Clinical trialUNITERAREApr 3
Researchers are looking for patients with a type of blood cancer called acute lymphoblastic leukemia (ALL) to test a new treatment combination. The study will test whether adding a drug called JZP458 to standard chemotherapy works better than chemotherapy alone. This trial is just starting and will recruit patients beginning in April 2026.
WHY IT MATTERSThis Phase 2 trial is now actively recruiting newly diagnosed ALL patients without the Philadelphia chromosome, offering access to an investigational asparaginase formulation (JZP458) that may have improved tolerability compared to standard asparaginase.
ResearchPUBMEDMar 26
Doctors are learning that common diseases are actually made up of many different rare subtypes when scientists look at their genetic makeup. By understanding the specific genetic changes in each person's disease, doctors can create targeted treatments that work better. This article uses chronic myeloid leukemia as an example—a treatment that targets one specific genetic change has turned a deadly disease into one people can live with for decades.
WHY IT MATTERSIf you have been diagnosed with a common cancer or disease, genetic testing may reveal you have a rare molecular subtype that qualifies you for a precision medicine treatment not available to patients with other genetic variations of the same disease.
ResearchPUBMEDMar 26
A 45-year-old man had ear canal swelling and an ear infection that wouldn't go away with normal treatment. Doctors performed surgery but didn't find the cause at first. After more testing, they discovered the real problem: cancer cells from a blood disease called acute myeloid leukemia (AML) had come back and were growing in the bone behind his ear.
WHY IT MATTERSThis case shows that persistent ear infections that don't respond to standard treatment could be a sign of leukemia relapse, meaning AML patients with unusual ear symptoms need urgent investigation beyond typical infection treatment.